Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

325.62 +12.90 (+4.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
After Regeneron, US Govt. Orders For Additional COVID-19 Therapy From Eli Lilly
The U.S. government has announced to purchase additional doses of Eli Lilly And Co's (NYSE: LLY) for its neutralizing antibody therapies for COVID-19. Related... 
Via Benzinga
Exposures COVID-19
U.S. Govt Calls For Additional Doses Of Regeneron's COVID-19 Antibody Therapy
The U.S. government will buy 1.4 million additional doses of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail. Read Next: ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
Where Eli Lilly Stands With Analysts
Analysts have provided the following ratings for Eli Lilly (NYSE:LLY) within ... 
Via Benzinga
Why Eli Lilly's COVID Antibody Therapy Is Making a Comeback
There's a one-word answer: delta. 
Via The Motley Fool
Exposures COVID-19
Baird Initiates BeyondSpring With Outperform On Plinabulin Potential
BeyondSpring Inc’s (NASDAQ:BYSI) lead candidate plin... 
Via Benzinga
Here's Why ProQR Stock Surged on Thursday
A new collaboration deal with Eli Lilly could be worth up to $1.3 billion. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers IVERIC bio (NASDAQ:ISEE) shares ... 
Via Benzinga
Why Shares of Johnson & Johnson Are Down 2% Today
The list of ideas is only the start of the legislative process. 
Via The Motley Fool
Delta Variant Fears Continue
The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher. 
Via Talk Markets
Biogen Stock Dives As CEO Admits 'Slower Than We Anticipated' Alzheimer's Drug Launch
Biogen stock tumbled Thursday after its CEO admitted the launch of Alzheimer's drug Aduhelm has been "slower than we anticipated." 
Via Investor's Business Daily
Eli Lilly Inks Another RNA Collab, This Time With ProQR
Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR... 
Via Benzinga
This Med Tech Innovator Just Doubled, And It Can Do It Again
We’re here to crush the market with the foremost innovative tech leaders. 
Via Talk Markets
Abbott Labs Stock Strength Rises Into New Percentile As Health Care Giant Expands Organically And Via Acquisition
Additionally, Chicago-based Abbott Labs stock carries a near-perfect 98 Composite Rating, putting it in the top 2% of all stocks. 
Via Investor's Business Daily
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
Wall Street Crime And Punishment: Martha Stewart's Perfectly Ridiculous Stock Scandal
Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition... 
Via Benzinga
FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know
The FDA wrapped up its long-awaited review of Pfizer Inc's (NYSE: PFE) large, randomized trial evaluating the safety of JAK inhibitors Xeljanz and Xeljanz XR... 
Via Benzinga
Exposures Product Safety
AbbVie Stock: Why A New FDA Order Hit It Harder Than Rivals Pfizer, Lilly
AbbVie stock collapsed Wednesday after the FDA said it would have to add a warning to the label for arthritis drug Rinvoq. 
Via Investor's Business Daily
Exposures Product Safety
Market Briefing For Wednesday, Sept. 1
Nuances and ambiguities dominate the market and even geopolitical scene at the moment. We are going to have hotter inflation than the Fed would like, but growth does matter, because we concurrently... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Can COVID-19 Antibody Treatment Help In High-Risk Cases? Mayo Clinic, nference Study Shows Potential
Mayo Clinic and nference are jointly conducting artificial intelligence-powered studies evaluating monoclonal antibodies for COVID-19 in patients with an elevated risk... 
Via Benzinga
Exposures COVID-19
Chemical Pharmaceutical Market May See Big Move : GlaxoSmithKline, Eli Lilly, AstraZeneca
Stay up-to-date with Chemical Pharmaceutical Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Topics Supply Chain
Exposures Supply Chain
A Peek Into The Markets: US Stock Futures Edge Higher After S&P 500, Nasdaq Hit Record Highs
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the S&P and the Nasdaq hit record closing highs in the previous session following... 
Via Benzinga
Topics Stocks
Exposures US Equities
Distribution Resumes Of Eli Lilly COVID-19 Antibody Therapies
After the US paused distribution of Eli Lilly And Co's COVID-19 antibody therapies in June, the pharmaceutical company says those therapies are once again being distributed. 
Via Talk Markets
Exposures COVID-19
Distribution Resumes Of Eli Lilly COVID-19 Antibody Therapies
After the US paused distribution of Eli Lilly And Co (NYSE: LLY)'s COVID-19 antibody therapies in June, the pharmaceutical company says those therapies are once again being... 
Via Benzinga
Exposures COVID-19
Here's What This Label Expansion Could Mean for Eli Lilly Investors
The pharmaceutical company's type 2 diabetes drug Jardiance was recently approved by the FDA for another indication. 
Via The Motley Fool
Exposures Product Safety
Eli Lilly, Boehringer Share Jardiance Data In Heart Failure Field
Eli Lilly And Co (NYSE: LLY) and Boehringer Ingelheim have rolled out full results of EMPEROR-Preserved phase 3 trial of Jardiance (empagliflozin) for heart... 
Via Benzinga
This Potential Indication Could Mean Profit for Eli Lilly Investors
Eli Lilly updated investors on its ongoing phase 3 trials to treat patients who have moderate to severe eczema with a new drug. 
Via The Motley Fool
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
The second-quarter earnings season was a strong one for the drug/biotech sector. 
Via Talk Markets
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Exposures COVID-19
Friday Fears and Other Stock News Updates
Toyota has cut its output 40% over fear of the Delta variant of Covid, plus shortages of electronics. This is terrifying markets outside the USA. And other global stock news updates. 
Via Talk Markets
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.